rivaroxaban accord
accord healthcare s.l.u. - rivaroksabaan - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombootilised ained - täiskasvanud patsientidel, kellele tehti plaaniline puusa- või põlveliigese asendamise operatsiooni venoosse trombemboolia (vte) ennetamine. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 for haemodynamically unstable pe patients. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 haemodynamically ebastabiilne pe patsientidel). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 ja 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
runaplax õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - rivaroksabaan - õhukese polümeerikattega tablett - 2,5mg 10tk; 2,5mg 60tk; 2,5mg 20tk; 2,5mg 100tk; 2,5mg 196tk; 2,5mg 168tk; 2,5mg 98tk
rivaroxaban teva õhukese polümeerikattega tablett
teva gmbh - rivaroksabaan - õhukese polümeerikattega tablett - 20mg 90tk; 20mg 112tk; 20mg 100tk; 20mg 200tk; 20mg 10tk; 20mg 14tk; 20mg 30tk; 20mg 98tk
rivaroxaban teva õhukese polümeerikattega tablett
teva gmbh - rivaroksabaan - õhukese polümeerikattega tablett - 15mg 14tk; 15mg 28tk; 15mg 200tk; 15mg 42tk; 15mg 30tk; 15mg 10tk; 15mg 98tk; 15mg 112tk
rivaroxaban teva õhukese polümeerikattega tablett
teva gmbh - rivaroksabaan - õhukese polümeerikattega tablett - 10mg 98tk; 10mg 5tk; 10mg 10tk; 10mg 28tk; 10mg 30tk; 10mg 100tk; 10mg 90tk; 10mg 112tk
rivaroxaban auxilia õhukese polümeerikattega tablett
auxilia pharma oÜ - rivaroksabaan - õhukese polümeerikattega tablett - 10mg 45tk; 10mg 30tk; 10mg 20tk; 10mg 50tk; 10mg 15tk; 10mg 42tk; 10mg 56tk; 10mg 10tk; 10mg 98tk; 10mg 5tk
rivaroxaban auxilia õhukese polümeerikattega tablett
auxilia pharma oÜ - rivaroksabaan - õhukese polümeerikattega tablett - 2,5mg 50tk; 2,5mg 15tk; 2,5mg 98tk; 2,5mg 28tk; 2,5mg 42tk; 2,5mg 30tk; 2,5mg 45tk; 2,5mg 10tk
rivaroxaban alembic õhukese polümeerikattega tablett
alembic pharmaceuticals europe limited - rivaroksabaan - õhukese polümeerikattega tablett - 2,5mg 168tk; 2,5mg 28tk; 2,5mg 30tk; 2,5mg 14tk; 2,5mg 56tk; 2,5mg 98tk; 2,5mg 196tk
rivaroxaban alembic õhukese polümeerikattega tablett
alembic pharmaceuticals europe limited - rivaroksabaan - õhukese polümeerikattega tablett - 10mg 5tk; 10mg 10tk
ticagrelor pharmascience õhukese polümeerikattega tablett
pharmascience international limited - tikagreloor - õhukese polümeerikattega tablett - 90mg 100tk; 90mg 10tk; 90mg 28tk; 90mg 30tk; 90mg 168tk; 90mg 56tk; 90mg 14tk